Lyra Therapeutics (LYRA) Proxy Filing summary

Executive summary

• Annual meeting scheduled for May 14, 2025, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote by May 13, 2025.

Voting matters and shareholder proposals

• Election of two Class II directors to serve until the 2028 annual meeting: C. Ann Merrifield and Harlan W. Waksal.

• Ratification of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2025.

• Approval of amendments to the certificate of incorporation to effect a reverse stock split at a ratio between 1-for-10 and 1-for-50, at the Board's discretion.

• Approval to adjourn the meeting if additional proxies are needed for the reverse stock split proposal.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals presented at the annual meeting.